Drugs / Rabbit Antithymocyte Globulin (RATG)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT04328727 Background | Nov 2020 → Jun 2022 | aplastic anemia | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00771875 Comparator | Sep 2008 → Dec 2012 | transplant rejection | University of Cincinnati | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rabbit Antithymocyte Globulin (RATG) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00771875 ↗ |
| Route | Intravenous | “r-ATG was administered intravenously at a dose of 2.5 to 3.5 mg/kg/day on Days 1-5” NCT04328727 ↗ |